N/A N=53 Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events
Cardiac Arrest
Primary: Mishel Uncertainty in Illness Scale Score - Family Member Form — 82.67; 88.18 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=779 Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Breast Cancer
Primary: Overall Survival According to Unadjusted Analysis — 24.2; 44.0 Months
N/A N=10 Tandem Freedom Feasibility Study 1
Diabetes Mellitus, Type 1
Primary: Severe Hypoglycemia Events — 0; 0; 0 number of events
Phase 2 N=142 A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain
Endometriosis
Primary: Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 (Percentage Change) — -27.35; -34.72; -41.57; -18.61 percentage of change…
N/A N=83 Texting to Promote Breastfeeding (TOPS)
Increased Breastfeeding
Primary: Number of Participants Who do Not Opt Out of Receipt of Text Messages — 40; 40 Participants — p=1
Phase 3 N=90 Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007
Pyruvate Kinase Deficiency
Primary: All Cohorts: Number of Participants With at Least One Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or…
Phase 2 N=47 A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
MPN (Myeloproliferative Neoplasms)
Primary: Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms…
N/A N=50 The Self-Sampling Pilot Study
Squamous Cell Carcinoma of the Anus
Primary: Presence of Squamocolumnar Cells — 11; 8; 12; 19 Participants
N/A N=300 Translating Data Science to Palliative Care
Alzheimer's Disease and Related Dementias
Primary: Palliative Care Refusal Rate — 50; 69; 61; 113 Participants — p=0.17
N/A N=26 Nicotine Flux, a Potentially Powerful Tool for Regulating Nicotine Delivery From Electronic Cigarettes
Nicotine Vaping
Primary: Change in Maximum Arterial Blood Nicotine Delivery (Cmax) — 3.75; 2.48; 8.12; 2.96 ng/ml
Phase 2 N=1,364 Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)
Dengue
Primary: Dengue Virus (DENV)-Neutralizing Antibody Titers as Measured by Virus Reduction Neutralization Test (VRNT) — 608.55; 703.19; 773.96; 109.05 Titer — p=<0.001
Phase 2 N=356 A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
Advanced Cancer
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) - Part 1 A and 1 B — 6; 11; 10; 1 Participants
N/A N=103 Mindfulness Based Stress Reduction for Parkinson's Disease: A Longitudinal Study
Parkinson's Disease
Primary: Parkinson's Disease Questionnaire-39 — -1.03; -3.04 change score — p=0.34
N/A N=27 Broadband Sound and Sleep
Noise Exposure
Primary: Time Spent in Slow Wave Sleep and Rapid Eye Movement (N3 + REM) — 188.5532184; 195.9798771; 209.51862074703; 176.4599674 Minutes
N/A N=20 Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery
Rotator Cuff Injuries · Shoulder Disease · Hallux Valgus
Primary: Average Daily Pain Intensity 1st Week — 2 units on a scale